Immtech Pharmaceuticals, Inc. has announced that the US Patent and Trademark Office issued a patent related to the manufacturing of Immtech's drug candidate compounds. Immtech has an exclusive, worldwide license. Under this patent, Immtech license agreement with the company's consortium of scientists.
The patent, entitled "Process for the synthesis of bis-aryl diamidoxime compounds," claims a method for making drug candidate compounds, such as Immtech's pafuramidine maleate (DB289). The patent names scientists from both, the University of North Carolina at Chapel Hill and Georgia State University as inventors.
Eric L. Sorkin, Immtech's chairman and CEO, stated, "With the issuance of this patent, Immtech now has worldwide exclusive rights over 150 patents, including claims to compositions, methods of use, and methods of manufacturing compounds in Immtech's large library. This patent will further augment our patent estate and commercialization efforts. We are proud of the scientific accomplishments of our partner scientists and excited about Immtech's targeted markets."